9681085

Source:http://linkedlifedata.com/resource/pubmed/id/9681085

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0020823, umls-concept:C0078257, umls-concept:C0144576, umls-concept:C0183683, umls-concept:C0205179, umls-concept:C0205390, umls-concept:C0210630, umls-concept:C0344211, umls-concept:C0376562, umls-concept:C0684249, umls-concept:C1171411, umls-concept:C1317973, umls-concept:C1521721, umls-concept:C2603343
pubmed:issue	6
pubmed:dateCreated	1998-10-15
pubmed:abstractText	We designed a phase I-II trial of three active agents, paclitaxel, ifosfamide, and vinorelbine, in advanced non-small-cell lung cancer (NSCLC) to: 1) define the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of paclitaxel with filgrastim (G-CSF) support; and 2) determine the overall response rate and median survival of patients treated on this regimen.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P30-CA14599
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Filgrastim, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	0923-7534
pubmed:author	pubmed-author:GolombHH, pubmed-author:HoffmanP CPC, pubmed-author:KraussS ASA, pubmed-author:MastersG AGA, pubmed-author:MauerA MAM, pubmed-author:SamuelsB LBL, pubmed-author:VokesE EEE, pubmed-author:WatsonSS, pubmed-author:WykaDD
pubmed:issnType	Print
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	677-80
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:9681085-Adult, pubmed-meshheading:9681085-Aged, pubmed-meshheading:9681085-Aged, 80 and over, pubmed-meshheading:9681085-Antineoplastic Agents, Alkylating, pubmed-meshheading:9681085-Antineoplastic Agents, Phytogenic, pubmed-meshheading:9681085-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9681085-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:9681085-Dose-Response Relationship, Drug, pubmed-meshheading:9681085-Female, pubmed-meshheading:9681085-Follow-Up Studies, pubmed-meshheading:9681085-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:9681085-Humans, pubmed-meshheading:9681085-Ifosfamide, pubmed-meshheading:9681085-Lung Neoplasms, pubmed-meshheading:9681085-Male, pubmed-meshheading:9681085-Middle Aged, pubmed-meshheading:9681085-Neoplasm Staging, pubmed-meshheading:9681085-Paclitaxel, pubmed-meshheading:9681085-Recombinant Proteins, pubmed-meshheading:9681085-Survival Rate, pubmed-meshheading:9681085-Vinblastine
pubmed:year	1998
pubmed:articleTitle	A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
pubmed:affiliation	Department of Medicine, University of Chicago, IL, USA. g-masters@nwu.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I